Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Kilari Discusses Frontline Treatment Selection Factors for mRCC
June 27th 2024During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.